Analysis of differentiation mechanism of peripherally induced Foxp3 positive T cells for application to cancer treatment
Project/Area Number |
23501284
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Tumor immunology
|
Research Institution | Mie University |
Principal Investigator |
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | 免疫抑制 / 腫瘍免疫 |
Research Abstract |
We have previously established a 2-step culture method for differentiating Foxp3- naive CD4+ T cells to Foxp3+ induced-regulatory T cells (iTregs). Firstly, we stimulate naive CD4+ T cells by anti-CD3 mAb and anti-CD28 mAb in the presence of Jak3 inhibitor for 3 days (conditioning stage). Secondary, we keep culturing Foxp3- iTregs precursor T cells to differentiate these cells to Foxp3+ iTregs in the presence of IL-2 for 3 days (differentiation stage). We analyzed what kind of factors could affect this protocol. In this study, we have identified that IL-2 signaling pathway was the main target of Jak3 inhibitor, and IL-4 was the strongest inhibiting cytokine in the differentiation stage from Foxp3- iTregs precursor cells to Foxp3+ iTregs. We also confirmed that STAT6, a downstream molecule of IL-4 signaling pathway, was an important molecule. These results obtained in this study are important for developing effective cancer treatment by regulating the differentiation into iTregs.
|
Report
(4 results)
Research Products
(35 results)
-
-
[Journal Article] Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients2013
Author(s)
Kageyama S, Wada H, Muro K, Niwa Y, Ueda S, Miyata H, Takiguchi S, Sugino SH, Miyahara Y, Ikeda H, Imai N, Sato E, Yamada T, Osako M, Ohnishi M, Harada N, Hishida T, Doki Y, Shiku H
-
Journal Title
J Transl Med
Volume: 11
Pages: 246-246
Related Report
Peer Reviewed
-
-
[Journal Article] Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients2013
Author(s)
Kageyama S, Wada H, Muro K, Niwa Y, Ueda S, Miyata H, Takiguchi S, Sugino SH, Miyahara Y, Ikeda H, Imai N, Sato E, Yamada T, Osako M, Ohnishi M, Harada N, Hishida T, Doki Y, Shiku H
-
Journal Title
Journal of translational medicine
Volume: 5;11
Issue: 1
Pages: 246-246
DOI
Related Report
Peer Reviewed
-
-
-
-
-
[Journal Article] H.Intratumoral injection of Propionibacterium acnes suppresses malignant melanoma by enhancing Th1 immune responses2011
Author(s)
Tsuda K, Yamanaka K, Linan W, Miyahara Y, Akeda T, Nakanishi T, Kitagawa H, Kakeda M, Kurokawa I, Shiku H, Gabazza EC, Mizutani
-
Journal Title
Related Report
Peer Reviewed
-
[Journal Article] Intratumoral injection of Propionibacterium acnes suppresses malignant melanoma by enhancing Th1 immune responses2011
Author(s)
K Tsuda, K Yamanaka, W ang L,Y Miyahara, T Akeda, T Nakanishi, H Kitagawa, M Kakeda, I Kurokawa, H Shiku, E C. Gabazza, and H Mizutani
-
Journal Title
PLoS One
Volume: 6(12)
Issue: 12
Pages: e29020-e29020
DOI
Related Report
Peer Reviewed
-
[Presentation] Adoptive transfer of wild-type TCR-gene transduced T lymphocytes targeting MAGE-A4 antigen to patients with refractory esophageal cancer2014
Author(s)
S Kageyama, H Ikeda, N Imai, M Ishihara, Y Miyahara, S Ueda, T Ishikawa, H Naota, K Ohishi, T Shiraishi, N Inoue, M Tanabe, T Kidokoro, H Yoshioka, D Tomura, I Nukaya, J Mineno, K Takesako, N Katayama, H Shiku
Organizer
American Assosication for Cancer Research Annual meeting
Place of Presentation
San Diego, CA, USA
Year and Date
2014-04-05
Related Report
-
[Presentation] Adoptive transfer of TCR gene-transduced lymphocytes targeting MAGE-A4 for refractory esophageal cancer2014
Author(s)
Y Miyahara, S Kageyama, H Ikeda, M Ishihara, N Katayama, D Tomura, I Nukaya, J Mineno, K Takesako, H Shiku
Organizer
ITOC-1 Immunotherapy of Cancer Conference
Place of Presentation
Munich, Germany
Year and Date
2014-03-12
Related Report
-
-
-
[Presentation]2013
Author(s)
H Ikeda, S Kageyama, N Imai, Y Miyahara, M Ishihara, N Katayama, H Yoshioka, D Tomura, I Nukaya, J Mineno, K Takesako, H Shiku
Organizer
28^<th> Annual Meeting of Society for Immunotherapy of Cancer
Place of Presentation
National Harbor, MD, USA
Year and Date
2013-11-07
Related Report
-
-
-
-
-
-
-
-
-
[Presentation] ANTIGEN RECEPTOR GENE-MODIFIED LYMPHOCYTES : HARNESSING T CELLS FOR EFFECTIVE CANCER TREATMENT WITH NOVEL VECTORS AND MANIPULATIONS2013
Author(s)
H Ikeda, S Kageyama, N Imai, Y Miyahara, M Ishihara, A Kawamura, M Yamane, D Tomura, S Okamoto, I Nukaya, J Mineno, K Takesako, N Katayama, H Shiku
Organizer
American Assosication for Cancer Research Annual meeting
Place of Presentation
Washington, DC, USA
Year and Date
2013-04-05
Related Report
-
-
[Presentation] Immuno-monitoring of adoptive immunotherapy using patient’s autologous T cells redirected by MAGE-A4 specific TCR gene transduction2013
Author(s)
Sahoko Sugino, Yoshihiro Miyahara, Shugo Ueda, Takeshi Ishikawa, Satoshi Kokura, Hiroaki Ikeda, Shinichi Kageyama, Ikuei Nukaya, Daisuke Tomura, Hirofumi Yoshioka, Junichi Mineno, Hiroshi Shiku
Organizer
日本癌学会
Place of Presentation
パシフィコ横浜
Related Report
-
-
-
-
-
-
-
[Presentation] Clinical application of TCR gene-transduced lymphocytes for patients with epitherial cancer and other types of malignancy: In vivo persistence of adoptively transferred TCR gene-transduced lymphocytes with anti-tumor reactivity in patients
Author(s)
H Ikeda, S Kageyama, N Imai, Y Miyahara, M Ishihara, N Katayama, H Yoshioka, D Tomura, I Nukaya, J Mineno, K Takesako, H Shiku
Organizer
2013 European society of gene & cell therapy (ESGCT) and SETGyC Collaborative Congress
Place of Presentation
Madrid, Spain
Related Report
-
-